Publications by authors named "Sonal Parasrampuria"

Claim this Profile
M
Measuring the First Mover Advantage in US Biosimilar Markets.
J Daniel McGeeney, Aylin Sertkaya, Samantha A McCormick, Andreas Lord, Ayesha Berlind, Sonal Parasrampuria

Value Health· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the Value of Adding 30 Days to the 180-Day Market Exclusivity of the First-to-File Generic Drug Manufacturer.
Aylin Sertkaya, Zeid El-Kilani, Sean Klein, Andreas Lord, Ruben Jacobo-Rubio, Sonal Parasrampuria

Pharmacoecon Open· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospice Coding and Data Conventions Contribute to Oversimplify the Presence of Dementia in Hospice.
Julia Driessen, Sonal Parasrampuria, Elvedin Bijelic, David M Bott, Shari M Ling

J Am Med Dir Assoc· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Premarket Notifications and Patents for Breast Pumps Before and After the ACA.
Oluwarantimi Adetunji, Pallavi Pemmireddy, Trinidad Beleche, Sonal Parasrampuria

JAMA· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disaggregating the dementia monolith: An analysis of variation in Medicare costs and use by dementia subtype.
Sonal Parasrampuria, Elvedin Bijelic, David M Bott, Julia Driessen, Michael J Lipp

Alzheimers Dement· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
Michael J DiStefano, So-Yeon Kang, Sonal Parasrampuria, Gerard F Anderson

JAMA Health Forum· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Electronic Prescribing of Controlled Substances on Opioid Prescribing: Evidence From I-STOP Program in New York.
Yuriy Pylypchuk, Sonal Parasrampuria, Carmen Smiley, Talisha Searcy

Med Care Res Rev· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of an out-of-pocket maximum in Medicare Part D.
Sonal Parasrampuria, Gerard F Anderson

Am J Manag Care· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".
William V Padula, Sonal Parasrampuria, Mariana P Socal, Rena M Conti, Gerard F Anderson

Pharmacoeconomics· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modifying the Criteria for Granting Orphan Drug Market Exclusivity.
Mariana P Socal, Sonal Parasrampuria, Gerard F Anderson

Value Health· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.
William V Padula, Sonal Parasrampuria, Mariana P Socal, Rena M Conti, Gerard F Anderson

Pharmacoeconomics· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance.
Sonal Parasrampuria, Aditi P Sen, Gerard F Anderson

Am J Manag Care· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VALUE AND PERFORMANCE OF ACCOUNTABLE CARE ORGANIZATIONS: A COST-MINIMIZATION ANALYSIS.
Sonal Parasrampuria, Allison H Oakes, Shannon S Wu, Megha A Parikh, William V Padula

Int J Technol Assess Health Care· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis